The lack of a clear guidance on the adequate number of animals used for positive controls in the short-term (26-weeks) transgenic mouse carcinogenicity studies has resulted in the use of high number of animals. In our earlier Tg.rasH2 studies, 25 mice/sex were used in the urethane-positive control dose groups that were sacrificed by 18 weeks. Based on a robust response, several of our protocols for Tg.rasH2 studies with 15 mice/sex and terminal sacrifice at 17 + 1 weeks were submitted and accepted by the Carcinogenicity Assessment Committee of the US Food and Drug Administration since we demonstrated close to 100 % response for the development of lung and splenic tumors (target organs) in 500 mice/sex. These 500 mice/sex included 17 groups ...
1. The objective of this investigation was to test the influence of mammary cancer tissue extract on...
Dose selection for the 6-month rasH2 mouse carcinogenicity studies depends heavily on the maximum to...
A factor limiting widespread use of the transgenic rasH2 mouse model for carcinogenicity testing of ...
The Tg.rasH2 mouse is a hemizygous transgenic mouse, approved by regulatory agencies for carcinogeni...
Transgenic animal models have been used in small numbers in gene function studies in vivo for a peri...
High doses in Tg.rasH2 carcinogenicity studies are usually set at the maximum tolerated dose (MTD), ...
Assessment of the skin tumor–promoting potential of 12-O-tetradecanoylphorbol-13-acetate (TPA) after...
Advances in genetic engineering have created opportunities for improved understanding of the molecul...
A factor limiting widespread use of the transgenic rasH2 mouse model for carcinogenicity testing of ...
SUMMARY-In an attempt to increase the occurrence of reticular neo-plasms by treatment with urethan a...
The Tg.rasH2 mouse was developed as a model for the alternative carcinogenicity testing. As an alter...
Alternate transgenic mouse models are accepted as replacements for the standard carcinogenicity mous...
rodent carcinogenicity tests on 241 pharmaceutical agents. Positive results were reported for 101 ag...
Alternate transgenic mouse models are accepted as replacements for the standard carcinogenicity mous...
1. The objective of this investigation was to test the influence of mammary cancer tissue extract on...
1. The objective of this investigation was to test the influence of mammary cancer tissue extract on...
Dose selection for the 6-month rasH2 mouse carcinogenicity studies depends heavily on the maximum to...
A factor limiting widespread use of the transgenic rasH2 mouse model for carcinogenicity testing of ...
The Tg.rasH2 mouse is a hemizygous transgenic mouse, approved by regulatory agencies for carcinogeni...
Transgenic animal models have been used in small numbers in gene function studies in vivo for a peri...
High doses in Tg.rasH2 carcinogenicity studies are usually set at the maximum tolerated dose (MTD), ...
Assessment of the skin tumor–promoting potential of 12-O-tetradecanoylphorbol-13-acetate (TPA) after...
Advances in genetic engineering have created opportunities for improved understanding of the molecul...
A factor limiting widespread use of the transgenic rasH2 mouse model for carcinogenicity testing of ...
SUMMARY-In an attempt to increase the occurrence of reticular neo-plasms by treatment with urethan a...
The Tg.rasH2 mouse was developed as a model for the alternative carcinogenicity testing. As an alter...
Alternate transgenic mouse models are accepted as replacements for the standard carcinogenicity mous...
rodent carcinogenicity tests on 241 pharmaceutical agents. Positive results were reported for 101 ag...
Alternate transgenic mouse models are accepted as replacements for the standard carcinogenicity mous...
1. The objective of this investigation was to test the influence of mammary cancer tissue extract on...
1. The objective of this investigation was to test the influence of mammary cancer tissue extract on...
Dose selection for the 6-month rasH2 mouse carcinogenicity studies depends heavily on the maximum to...
A factor limiting widespread use of the transgenic rasH2 mouse model for carcinogenicity testing of ...